Beneficence is one of three core ethical principles in the Belmont Report, and it boils down to two rules: do not harm research participants, and maximize the potential benefits of research while minimizing the risks. Published in 1979 after nearly four years of deliberation, the Belmont Report remains the foundational document governing the ethics of human subjects research in the United States.
The Two Rules of Beneficence
The Belmont Report frames beneficence not as an act of kindness or charity but as a binding obligation. It breaks the principle into two complementary parts. First, researchers cannot knowingly harm the people involved in their studies. Second, researchers must design their work to make the benefits of participation as large as possible while keeping risks as small as possible.
These two ideas, sometimes described as “do no harm” and “maximize benefits, minimize harms,” work together. Avoiding harm is the baseline. Actively seeking to improve outcomes for participants and for society is the higher standard. The report treats both as equally necessary, not optional aspirations.
Why Beneficence Was Written Into the Report
The Belmont Report exists because of a series of research scandals, the most notorious being the Tuskegee Syphilis Study. Starting in 1932, hundreds of poor Black men in Macon County, Alabama were deliberately left untreated for syphilis for 40 years so researchers could observe the disease’s progression. When the public learned of the study in 1972, the outcry was immediate. Congress created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, which spent years developing the ethical framework that became the Belmont Report.
The commission understood that simply telling researchers to “be ethical” was too vague. Beneficence gave reviewers and investigators a concrete standard: every study must demonstrate that the potential benefits justify the risks, and that those risks have been reduced as far as the research design allows.
How Beneficence Sits Alongside the Other Two Principles
The Belmont Report identifies three principles total: respect for persons, beneficence, and justice. Respect for persons deals with informed consent and the protection of people who can’t make decisions for themselves. Justice addresses who bears the burdens of research and who receives its benefits, ensuring that vulnerable populations aren’t unfairly targeted as test subjects while wealthier groups reap the rewards.
Beneficence occupies the middle ground. Where respect for persons asks “did the participant choose freely?” and justice asks “is this fair?”, beneficence asks “does the potential good of this study outweigh the potential harm?” All three principles must be satisfied before research can proceed.
What Counts as Harm, and What Counts as Benefit
The report defines harm broadly. Physical injury and pain are the most obvious risks, but the framework also requires researchers to account for psychological harm, legal harm, social harm, and economic harm. A study that exposes sensitive personal information, for example, could damage a participant’s reputation or employment prospects. That counts.
Benefits are similarly broad. They can include direct improvements to a participant’s health, new knowledge that helps future patients, or advances in understanding that benefit society at large. The report is clear, though, that benefits to society don’t automatically justify risks to individuals. The well-being of the actual person in the study carries special weight. A study can proceed based primarily on its value to science or the public, but only when the participant’s rights have been protected and the risks remain reasonable.
How Beneficence Works in Practice
Before any study involving human participants can begin at a research institution, it must be reviewed by an Institutional Review Board (IRB). The IRB’s job, in part, is to apply the principle of beneficence by evaluating whether the risks to participants have been minimized and whether those risks are reasonable given the anticipated benefits. The board can approve, require changes to, or reject a study that doesn’t meet this standard.
This means beneficence shapes research long before a single participant enrolls. Investigators are expected to build risk reduction into their study design from the start, choosing the safest effective methods, limiting exposure to only what’s necessary, and planning for how to handle adverse events. It’s not enough to have a good research question. The way you pursue the answer has to reflect genuine concern for the people involved.
Balancing Individual and Societal Interests
One of the more difficult aspects of beneficence is that benefits to individuals and benefits to society don’t always align. A clinical trial might offer no direct benefit to the participant but could generate knowledge that saves thousands of lives in the future. The Belmont Report acknowledges this tension directly, noting that “the different claims covered by the principle of beneficence may come into conflict and force difficult choices.”
The report’s guidance is nuanced. It states that risks and benefits affecting the immediate research subject will “normally carry special weight,” but it also recognizes that broader societal interests can sometimes justify research risks on their own. The obligation of beneficence extends beyond individual investigators to society at large. The public has a stake in supporting research that improves medical treatments and social interventions, and that means accepting some level of risk in well-designed, ethically reviewed studies. The key safeguard is that no study should proceed unless its risks have been carefully weighed against its potential gains, with the participant’s welfare at the center of that calculation.